TP53 and Angelman syndrome: UBE3A has been extensively investigated due to its ability to ubiquitinate the p53 tumor suppressor upon human papillomavirus infection[42] and due to its clinical significance with mutations causing Angelman syndrome and Prader‐Willi syndrome.